BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 6, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for Oct. 14, 2022

Oct. 14, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bavarian Nordic, Cantargia, Edgewise, Enliven, Forma, Imara, Novo Nordisk.
Read More

In the clinic for Oct. 14, 2022

Oct. 14, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D-Pharma, Agenus, Albireo, Biocorrx, Biontech, Cassava, Compass, Crinetics, Inotrem, Inovio, Novavax, Ocugen, Otonomy, Pfizer, Relmada, Sifi, Siga, Smart Immune, Vectivbio.
Read More

Regulatory actions for Oct. 13, 2022

Oct. 13, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aim, Biomind, Eagle, Elevar, Galectin, Merck & Co., Moerna, Pfizer, Regeneron, Sisaf.
Read More

In the clinic for Oct. 13, 2022

Oct. 13, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Amolyt, Atai, Avidity, Beigene, Cognition, Corcept, Eupraxia, Evgen, Evofem, Frequency, Fulcrum, Genentech, Janux, Junshi, Kinnate, Leap, Novavax, Sangamo.
Read More

Other news to note for Oct. 13, 2022

Oct. 13, 2022
Additional early-stage research and drug discovery news in brief, from: Codiak, Dyne, Halberd.
Read More

Moderna strengthened by Merck deal and new COVID-19 vaccine EUA

Oct. 12, 2022
By Lee Landenberger
It was a busy day at Moderna Inc. as Merck & Co. Inc. exercised its option to jointly develop and commercialize a personalized cancer vaccine with Moderna in a deal the two companies inked in 2016. Moderna also notched another emergency use authorization (EUA) for its COVID-19 vaccine, this one targeting the omicron variant, for use by those under age 18.
Read More

Other news to note for Oct. 12, 2022

Oct. 12, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aadi, Agenus, Allomek, CLS, Emergex, Immunoprecise, Ligand, Mendus, Mirati, Mirum, Nervgen, Omega, Omniab, Oncotelic, Pasithea, Renbio, Synthetic, Talem, Toregem, VBI, Viewpoint Molecular, Wuxi, Xentic, Zosano.
Read More
HKEX on phone, digital stock chart

Aim Vaccine gains HKEX listing, raises $9M for COVID-19, pneumococcal candidates

Oct. 11, 2022
By Doris Yu
Aim Vaccine Co. Ltd. priced an IPO on the Hong Kong Stock Exchange, raising HK$70.01 million (US$9 million) to fund work on its late-stage vaccine pipeline. Its shares increased only 3.09% on debut Oct. 6 but closed the week at HK$24.80, up 54% over its listing price of HK$16.16.
Read More

Regulatory actions for Oct. 11, 2022

Oct. 11, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Everest, GSK, HDT, Innovent, Nanoscope, Novelmed, Pfizer, Scpharmaceuticals, Supernus.
Read More

Other news to note for Oct. 11, 2022

Oct. 11, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Brooklyn, Cara, Christianacare, Cocrystal, Corrixr, Compass, Eli Lilly, Enteris, Eterna, ICER, Karuna, Merck and Co., Muna, Nimbus, Psychogenics, SWK and Synergys.
Read More
Previous 1 2 … 73 74 75 76 77 78 79 80 81 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 5, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Auvelity

    Axsome’s Auvelity cleared for large Alzheimer’s agitation market

    BioWorld
    Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
  • Pancreas

    Sonire starts US study of cancer HIFU after $18M series A

    BioWorld
    Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
  • Coreterra Therapeutics patents agents for schizophrenia

    BioWorld Science
    Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing